CHMP recommends acoramidis for EU approval based on positive Phase 3 study results, with a final decision expected soon.Quiver AI SummaryThe Committee for Medicinal Products for Human Use (CHMP) has recommended...
Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.
BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...
Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...
BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...
Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...